The fusion protein BCR–ABL1, a constitutively active tyrosine kinase, is the unique hallmark and main driver of CML leukemic cells and LSCs, as it is present in >90% of the patients [179]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.